IBD in 2013: Enriching the therapeutic armamentarium for IBD

Silvio Danese, Laurent Peyrin-Biroulet

Research output: Contribution to journalArticlepeer-review


In 2013, several new IBD drugs, including golimumab and vedolizumab, have been approved or completed successful programmes, showing efficacy in both Crohn's disease and ulcerative colitis. In addition, classic IBD drugs have been formulated for colonic delivery, such as budesonide MMX, which was recently approved for mild-to-moderate ulcerative colitis.

Original languageEnglish
Pages (from-to)84-86
Number of pages3
JournalNature Reviews Gastroenterology and Hepatology
Issue number2
Publication statusPublished - Feb 2014

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'IBD in 2013: Enriching the therapeutic armamentarium for IBD'. Together they form a unique fingerprint.

Cite this